T argeting Ag to dendritic cells (DCs), by injecting Ag coupled to a mAb specific for a DC surface molecule, is an established experimental strategy for enhancing immune responses and has the potential for improving the efficiency of vaccines (1) (2) (3) . Such enhanced immune responses are considered to result from more effective presentation of the Ag by the targeted DC to Ag-specific T cells. The C-type lectin-like molecule Clec9A (also called DNGR1) has proved to be a very effective target molecule for this application. Clec9A is a dead cell recognition molecule, the ligand being F-actin exposed when the cell membrane is disrupted (4) (5) (6) ). An advantage of Clec9A for targeting applications is that expression is restricted to certain DCs. In mice, Clec9A is selectively expressed by the CD8 + DC lineage and its migratory equivalent, the CD103 + DCs, with lower expression on plasmacytoid DCs; it is not expressed on lymphocytes or other hematopoietic cells (7) (8) (9) (10) . In humans it is expressed on BDCA3 + DCs, the equivalent of the murine CD8 + DC lineage. Targeting Ag to Clec9A results in very effective CD4 and CD8 T cell proliferative responses; with coadministration of adjuvants to activate the DCs, this leads to the generation of effector cytotoxic T cells (8, 9, 11) . In this latter respect, targeting Clec9A gives responses similar to those obtained by targeting DEC-205, another molecule strongly expressed by CD8 + DCs (11) (12) (13) . One surprising feature of the responses obtained by targeting protein Ag to DCs, using the anti-Clec9A mAb we have generated, is the high Ab responses obtained even in the absence of adjuvants or signs of DC activation (9) . One reason for this is a prolonged CD4 T cell response that results in the production of T follicular helper cells (T FH ), which in turn is a result of persistence of the Ag-anti-Clec9A construct in the serum and consequent prolonged Ag presentation by the targeted DCs (11) . This result differs from targeting other DC surface molecules such as DEC-205. With DEC-205, the targeting construct is rapidly removed from the serum, the T cell response is transient, regulatory T cells are generated, and Ab responses are minimal unless the DCs are activated with adjuvants (11, 14) . However, other observations have been made of effective Ab responses on targeting Ag to other DC surface molecules, even in the absence of adjuvant (3) . In one recent study targeting nitrophenol (NP)-protein conjugates to DC-inhibitory receptor 2 on the surface of a subset of marginal zone CD8
2 DCs, an effective Ab response to NP was obtained in the absence of adjuvant (15) . This finding was shown to be an extrafollicular but T cell-dependent response, strongly enhanced by the DC-induced helper T cell generation, dependent on an indirect pickup and subsequent presentation of Ag by the B cell component. We now focus on the B cell response when Ag is targeted to Clec9A, using the well-established B cell hapten NP (16) conjugated to a mAb against Clec9A, which, being a rat Ig, serves as carrier with an effective helper T cell epitope in C57BL/6 mice (9). Targeting tiny amounts of NP-Ig to Clec9A in the absence of adjuvant gave very high anti-NP Ab responses with the initial features of a follicular response, including some affinity maturation and memory B cell generation. The serum response was prolonged, Ab persisting at high amounts even when other aspects of the B cell response had diminished. Because protection against many infectious diseases depends on Ab production, these findings have many implications for the enhancement of vaccine effectiveness by targeting to Clec9A.
Materials and Methods

Animals
The mice used were 8-to 12-wk-old C57BL/6 females, bred and maintained under specific pathogen-free conditions at the Walter and Eliza Hall Institute. All animal procedures were approved by the Walter and Eliza Hall Institute Animal Ethics Committee.
by spectrophotometry. The NP coupled to keyhole limpet hemocyanin (KLH) (NP 19 -NP 20 ) was precipitated in alum (16, 17) . Immunizations were usually performed using 2 mg NP-conjugated Abs (anti-Clec9A-NP and isotype control-NP) administered by i.v. injection (9) or with 100 mg alum-precipitated NP-KLH (NP-KLH/alum) administered by i.p. injection (16) .
ELISA assay for anti-NP serum Ab
Anti-NP Ab titers were normally determined by ELISA assay exactly as described (16) . To calculate the exact titer and the anti-NP IgG1 concentration, a standard curve was made using GSX2.1, an IgG1 NP-specific hybridoma utilizing V H 186.2 (18) . On the basis of this curve, a titer of 10 5 corresponded to 388 mg/ml IgG1, whereas a titer of 10 4 corresponded to 24 mg/ml. For the other Ig isotypes for which standard curves were not constructed, an endpoint titer of 10 SDs above a no serum-negative control was used.
ELISA assay for anti-rat Ig serum Ab
For anti-rat Ig serum levels, the ELISA assay was as previously described (9) . In the blocking assay for relative affinity, serum was first preincubated with 10 mg or 50 mg rat Ig for 30 min at room temperature, and the mixture was then transferred into the ELISA assay plates. The percentage blocking by rat Ig was enumerated based on the OD readings given by unblocked serum samples.
NP-specific B cell assays
Ag-specific B cells were prepared and stained for flow cytometric analysis exactly as described (16 
Immunohistology
Spleens from the immunized mice were embedded and frozen in OCT (Tissue Tek; Sakura) at 280˚C. Sections of size 7 mM were cut using a microtome (Leica) and then stained as follows: rat anti-B220 (RA3-6B2) and biotinylated peanut agglutinin, then anti-rat k-HRPO (3090-05; Southern Biotech) and streptavidin alkaline phosphatase (7100-04; Southern Biotech). The color was developed using AEC Substrate (SK4200; Vector Laboratories) and FastBlue (SK5300; Vector Laboratories) for visualization of the peroxidase and the alkaline phosphatase, respectively. Images were taken on an Axioplan 2 imaging microscope (Carl Zeiss).
Statistics
Statistical analysis was performed using Prism software (GraphPad software). A two-tailed unpaired Student t test was used for differences between anti-Clec9A NP and isotype control NP, and one-way ANOVA was used for differences among three groups. The p values are indicated as follows: *p , 0.05, **p , 0.01, ***p , 0.001, and ****p , 0.0001. 
Results
Serum Ab responses on targeting NP to Clec9A
To determine if the high Ab responses previously obtained by targeting protein Ag to Clec9A would also be obtained to a defined B cell hapten, 2 mg of NP conjugated to anti-Clec9A mAb (the rat IgG2a mAb 24/04-10B4) (9) was injected i.v. into C57BL/6 mice. The response was compared with an i.v. injection of 2 mg of NP conjugated to an isotype-matched nontargeting mAb (the rat IgG2a mAb GL117). The response to these small amounts of targeted NP without adjuvant was compared with the response obtained under conditions known to give high Ab titers, namely, injection of 100 mg of NP coupled to KLH in alum as adjuvant. Targeting NP-rat Ig to Clec9A in this way gave a strong serum Ab response with a single injection, compared with the marginal response obtained following injection of untargeted NP-rat Ig (Fig. 1A) . The response peaked 2-3 wk post injection with an anti-NP IgG1 titer of corresponding to 0.39 mg/ml. The response dropped after 3 wk, declining slowly such that significant serum Ab titers were maintained beyond 35 wk after this single injection. Although IgG1 dominated the anti-NP Ab response, other Ig isotypes were also produced ( Fig.  2) . Overall, the targeted anti-NP Ab response was similar to those previously reported using the protein Ags OVA and rat Ig, which were shown to be T cell and DC dependent (9, 11) .
Although the anti-NP Ab response obtained by injecting 2 mg of NP-anti-Clec9A without adjuvant was at the peak a little less than that obtained by i.p. injection of 100 mg of NP-KLH in the presence of alum as adjuvant, the persistence of the response was more marked, so by 4 wk the titers were equivalent (Fig. 1A) . This finding is in line with the results for protein Ag, in which targeting to Clec9A in the absence of adjuvants gave Ab responses comparable to those obtained using adjuvants (9, 11) . However, for the same small amount of NP-protein injected, targeting to Clec9A gave a better response even at the peak than that obtained using alum as adjuvant. Thus, in one experiment, when 2 mg of NPisotype control construct instead of 100 mg of NP-KLH was administered i.p. with alum adjuvant, only 0.003 6 0.002 mg/ml of anti-NP IgG1 was obtained by 2 wk, whereas 2 mg of NP-antiClec9A injected i.v. without adjuvant gave 0.24 6 0.07 mg/ml of anti-NP IgG1.
B cell responses on targeting NP to Clec9A
An advantage of using NP as Ag is that techniques are available for monitoring the dynamics of the response of the NP-specific B-lineage cells. These techniques were used to examine the basis of the serum Ab responses. Following injection of the NP-antiClec9A complex, NP-binding B cells expanded to represent up to 3% of the total spleen B cells at day 7, although this number dropped to much lower levels by 2 wk and remained low thereafter (Fig. 1B) . No such response was detected with the same quantity of untargeted NP-protein. The response was below that obtained using a high dose of NP-KLH with alum, in line with the initial difference in Ab production. The frequency of NP-specific AFCs in the spleen, as detected by ELISPOT also peaked around day 7, and the number was only a little lower than that obtained with high-dose NP-KLH with alum (Fig. 1C) . However, the frequency of NP-specific AFC following a low dose of targeted NP then fell rapidly after day 7, much more so than was observed following the high-dose NP-KLH with alum. The results in Fig. 1 revealed a surprising characteristic of the response to the Clec9A-targeted Ag. In the case of high-dose NP-KLH in alum, the frequency of NP-specific AFCs detected in the spleen over the 6-wk period was reasonably in line with the anti-NP serum Ab titer. However, in the case of the low-dose Clec9A-targeted Ag, the frequency of NP-specific AFCs in the spleen dropped around 10 3 -fold, whereas the NP-specific Ab titer dropped only 10-fold. The "missing" AFCs were sought elsewhere in the mice, particularly in bone marrow (BM). In the case of high-dose NP-KLH plus alum, AFCs in the BM increased between 1 and 3 wk post injection, but in the case of the low-dose Clec9A-targeted Ag, the AFC frequency in BM dropped over this period (Fig. 1D) . Other sites in the Clec9A-targeted mice, including blood, lymph nodes, and GALT, did not reveal any AFC accumulation or high AFC frequency over this period. However, it is important to note that 6 wk after injection the Clec9A-targeted mice retained AFCs in spleen and BM at a frequency above that detected following injection of the same quantity of untargeted NP-rat Ig (Fig. 1C, 1D) . We concluded that the persistent high serum Ab titers following targeting of NP-rat Ig to Clec9A were produced by a relatively low frequency of persistent, efficient AFCs.
Germinal center formation and affinity maturation on targeting NP to Clec9A
Our previous studies on the Clec9A-targeted response to OVA had demonstrated a remarkable generation of T FH cells, some of which were located in the GCs of the B cell follicles (11) . Accordingly, we asked whether the B cell response to Clec9A-targeted NP would involve germinal center (GC) formation and affinity maturation of the anti-NP Ab. Affinity maturation at the level of the individual AFC was measured by comparing the ELISPOT count using an Ab capture protein with 1 NP conjugated per protein molecule (high affinity) versus 16 NP per molecule (total affinity). Following targeting of NP to Clec9A, an increase in the relative number of high affinity AFCs was observed over the initial 5-to 14-d period, an increase similar to that seen upon immunization with NP-KLH in alum (Fig. 3A) . Although accurate assessment could not be made beyond this time because of the low number of AFCs present, it was clear that the relative affinity of the AFCs produced following Clec9A targeting fell after day 14, indicating that the higher affinity AFCs had disappeared from the spleen (Fig. 3A) . In contrast, continuing production of high affinity AFCs was maintained in the spleen following immunization with NP-KLH/alum. In contrast to the ELISPOT data, the relative affinity Fig. 2 , a thicker lined circle, a gray marked circle, and a thinner lined circle represents mice that were immunized with anti-Clec9A-NP, isotype control-NP, and NP-KLH/alum, respectively. (C) GC staining of spleens from C57BL/6 mice 11 d postimmunization. GCs were revealed with peanut agglutinin (blue) and B cell follicles with anti-B220 (red). Scale bars, 100 mm. The histology shown is representative of six mice from two experiments. The graph shows the percentage of follicles with GCs as the mean 6 SEM. Data were analyzed by an unpaired two-tailed Student t test and significance was indicated as *p , 0.05, **p , 0.01, ***p , 0.001. of the serum Ab produced in the mice could be accurately monitored over the entire response, using the relative titer when NP 1 versus NP 16 was used as the capture Ag in the ELISA assay (Fig.  3B) . In response to Clec9A-targeted NP, there was an increase in the affinity of the anti-NP Ab produced over the first 28 d and especially over the first 14 d. However, in accordance with the transient production of high affinity AFCs, serum Ab affinity maturation was substantially less than that obtained with the high-dose NP-KLH/alum schedule, in which high affinity AFCs persisted in the spleen.
The incidence of GCs in the spleen B cell follicles following immunization with NP-anti-Clec9A was assessed by immunohistochemistry. An increase in GCs, compared with GCs in mice immunized with NP conjugated to the nontargeting isotype-matched control, was seen by 7 d and was statistically significant at 11 d (Fig.  3C) . This difference disappeared by 14 d. In contrast, immunization with NP-KLH and alum gave a higher incidence of follicles, with GCs maintained over the entire 1-to 2-wk period (data not shown). Overall, we concluded that part of the early response to targeting tiny amounts of NP-rat Ig to Clec9A involves a follicular response, with GC formation and Ab affinity maturation. However, this GC response is transient and shorter than that obtained with the NP-KLH/alum schedule.
Alignment of the anti-rat Ig response with the anti-NP response
Because our previous studies had been with protein Ag, it was important to know if the anti-NP Ab response resembled the antiprotein Ab response. Because the Clec9A-targeting mAb and the carrier protein for the NP immunization was a rat IgG2a, it was possible to monitor the serum anti-rat Ig response as well as the anti-NP response to the same immunogen. The anti-rat Ig titer (Fig.  4A) showed a similar time course to that of the anti-NP titer (Fig.  1A) , with a similarly prolonged Ab response. We had no assay for affinity maturation of the anti-rat Ig response at the AFC level, but an estimate of relative affinity at the serum Ab level could be obtained by measuring the extent of blocking of the final ELISA assay by preincubation of the serum dilutions with various concentrations of rat Ig. Over the 7-to 42-d period, the anti-rat Ig in the serum became more readily blocked by preincubation with rat Ig, so accordingly increased in affinity (Fig. 4B) . By these criteria the anti-NP response appeared similar to the anti-protein response.
Are memory B cells generated on targeting NP to Clec9A?
We had previously demonstrated that the initial Ab response to protein Ag targeted to Clec9A could be boosted, once the serum Ab had declined from the peak, by a secondary injection of even untargeted free Ag [(9); I. Caminschi and K. Shortman, unpublished observations]. However, whether this indicated the presence of memory B or memory T cells, or was due to other effects, was not clear. We tested the effect of secondary injections of either 2 mg of targeted NP-rat Ig, or 50 mg of untargeted NP-rat Ig, at 14 and 21 d after the primary targeted immunization but observed no boost to the already high anti-NP titers. A significant boost to the anti-NP titer was obtained in one experiment by the second injection of 2 mg of targeted NP-rat Ig 242 d after the first injection; this appeared to be a true memory response because the Ab produced showed a significantly increased affinity. However, we sought more direct evidence for memory at the B cell level.
The rapid decline in NP-specific B cells when NP was targeted to Clec9A (Fig. 1B) argued against the presence of a very large memory B cell generation relative to the primary B cell response. To determine in a functional assay if any memory B cells were generated, B cells were isolated from mice 42 d postimmunization with 2 mg of NP-anti-Clec9A, or from mice similarly immunized with nontargeting NP-isotype-matched control, or from mice immunized with 100 mg of NP-KLH and alum, or from unimmunized mice. The B cells were then transferred into recipient mice that had been preimmunized with KLH in alum to produce KLH-specific Th cells. These recipient mice were then challenged by injection of NP-KLH, and the total affinity anti-NP Ab response followed (Fig. 5) . When the total serum anti-NP response was measured, little sign of memory B cell generation was present, not even from mice primed with the high-dose NP-KLH plus alum schedule. However, when the readout was restricted to high affinity serum Ab, it was clear that the B cells from mice preimmunized by Clec9A targeting and by high Ag dose plus adjuvant gave a more rapid response with a higher titer at the early, 5-to 7-d period (Fig. 5) . This difference in titer was no longer evident over the day 14-28 peak response period. We concluded that Clec9A targeting of NP did generate some rapidly responding, high affinity memory B cells, but their contribution was eventually swamped by the large response from the primary B cells.
Discussion
This study, using the well-characterized B cell epitope NP, has confirmed and extended the main findings from our previous work with protein Ags (9, 11), namely, that targeting small amounts of Ag to Clec9A on DCs using an anti-Clec9A mAb produces a strong and persistent Ab response even without adjuvants. The initial response to Clec9A-targeted NP has the characteristics of a follicular response, with a transient formation of GCs, a degree of affinity maturation of the Ab produced, and the generation of some fast-responding high affinity memory B cells. The likely mechanism would be that the NP-rat Ig targeted to Clec9A on the surface of DCs of the CD8 + DC family leads to effective Ag presentation by these DCs. The persistence of anti-Clec9A in the serum, as previously demonstrated (11) , leads to continuous loading of rat Ig T cell epitopes on MHC class II, even in the absence of DC activation. In line with the striking generation of T FH cells found using OVA as Ag (11), these conditions should promote efficient production of T FH cells specific for rat Ig. In the simplest model, the persistence of NP-anti-Clec9A in the serum also allows B cells to encounter the NP hapten, and the T FH /B cell interaction then drives the follicular response.
One unresolved issue with this model is whether the enhanced Ab response on targeting Ag to Clec9A on DCs can be entirely explained by the efficient production of Th cells, specifically T FH cells, that we have previously documented (11) . Another possibility is that the Clec9A + DCs may present Ag to both T and B cells. Several studies have suggested that DCs may present Ag to B as well as to T cells (19, 20) .
One striking feature of the Ab response to NP following targeting to Clec9A not readily explained by these models is the prolonged serum Ab titer, persisting well after signs of a GC response have faded and when the number of AFCs in the spleen, BM, and other sites has dropped to a relatively low level. A proportion of the targeted response may be extrafollicular, as has been reported for the anti-NP response on targeting DC-inhibitory receptor 2 on DCs (15) . According to this model, the DCs may "hand on" the Ag to B cells, which then provide ongoing Ag presentation to T cells. Regardless of the mechanism driving the prolonged Ab response, the result suggests that the few remaining AFCs are very efficient, producing, in addition to the observed higher affinity Abs, either more Abs or Abs with prolonged serum persistence, compared with the AFCs seen early in the response. They also appear more efficient than the AFCs remaining after the conventional immunization with a high dose of Ag in alum adjuvant.
Effective immunization should involve the generation of memory B cells. Although the response to protein Ag can be boosted by secondary injection of the Ag, we obtained little boosting of the Ab response to NP; this may have been a consequence of the primary response being so high, at a near maximal ceiling. The very high primary response to NP also made it difficult to detect B memory cell generation, even with the high-dose NP-KLH plus adjuvant system. Despite this swamping by a primary response, it was possible to detect some rapidly responding, high affinity NP-specific memory B cell activity in mice primed by targeting NP to Clec9A.
The high and persisting Ab responses arising from a single injection of tiny amounts of Ag targeted to Clec9A, together with the finding that this response can be obtained without the secondary effects of adjuvants, suggests this approach could be applied to putative vaccine Ags for certain infectious diseases in which Ab is known to provide protection. Our experiments with NP as the model Ag provide some information relevant to this objective. Clearly, for Ab responses the Ag-anti-Clec9A construct used for targeting should maintain the B cell epitopes intact-not always a simple task if conformational B cell epitopes are involved. An alternative is not only to target the T cell epitopes to Clec9A to produce enhanced T cell help but also to use some form of untargeted Ag containing the B cell epitopes to induce B cell activation.
Model Ag used for laboratory studies has been selected as giving good immune responses, probably reflecting a naturally high frequency of precursors responsive to that Ag. The NP system may be an extreme example of this situation, because the primary response is so high it was difficult to see a secondary boost. Such an initially high incidence of Ag-specific B or T cells may not apply to many putative vaccine Ags, for which a low initial precursor frequency means even a primary response enhanced by Clec9A + B cells were isolated from each immunized mice group as well as from an unimmunized control group. The B cells were transferred into recipient C57BL/6 mice that had been immunized with 50 mg KLH in alum. The recipient mice were then challenged by injection of 50 mg soluble NP-KLH without alum. The titer of serum anti-NP IgG1 Ab was determined by ELISA at the indicated times after transfer, using NP 1 BSA (high affinity) or NP 16 BSA (total affinity) for Ab capture. Titers are shown as mean 6 SEM. Results represent one experiment with five mice per time point; the results were confirmed in a second experiment. Data were analyzed by one-way ANOVA analysis, followed by multiple comparisons, with significance indicated as ****p , 0.0001.
targeting may be inadequate for protective immunity. In such cases some form of priming, possibly requiring adjuvants, may be needed to enhance the precursor frequency prior to a boost involving Clec9A targeting.
Our experiments point to some issues that need to be overcome prior to such a prime-boost approach. One problem with a secondary injection of Clec9A-targeted Ag is that any Ab generated in the primary injection would remove the targeting construct from the bloodstream; we have demonstrated that prolonged persistence of the Ag-anti-Clec9A construct in the bloodstream is a major reason for its effectiveness (11) . Generation of memory B and T cells without generating a blocking Ab is a requirement. This limitation may be overcome using a different form of the Ag for the prime or the boost, limiting the targeting construct to a single administration.
These likely problems do not seem insurmountable, and many solutions could emerge from a detailed study of the Clec9A-targeted response, even using laboratory model Ags. It is important that CLEC9A is expressed in a similar way in the human DC system (7-9), and we have found that mAb against human CLEC9A can serve to target protein Ags in primates and enhance Ab production in a way that closely parallels the effects in mice (M.H. Lahoud, R. De Rose, S.J. Kent, A.M. Lew, K. Shortman, and I. Caminschi, manuscript in preparation). The use of CLEC9A targeting to enhance immunity and improve vaccines therefore has sufficient promise to justify further detailed study of the immunological mechanisms involved and to devise strategies for its effective implementation.
